Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Inclusion Criteria

• •Women with stages II-IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have completed standard therapy for primary or recurrent disease (i.e., patients who would normally be observed); eligible patients may have asymptomatic residual measurable disease on physical examination and/or computed tomography (CT) scan, and/or may have an elevated cancer antigen 125 (CA-125); or may be in complete clinical remission after treatment for primary or recurrent disease; these patients would normally enter a period of observation after standard management
• •Any human leukocyte antigen (HLA) type (historic HLA typing is permitted)
• •Tumor expression of NY-ESO-1 by immunohistochemistry (IHC) and/or real-time polymerase chain reaction (RTPCR)
• •No history of previous severe allergic reactions to vaccines or unknown allergens
• •Life expectancy \> 6 months
• •Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2
• •Hematology and biochemistry laboratory results within the limits normally expected for the patient population, without evidence of major organ failure
• •Absolute neutrophil count (ANC) \>= 1,000/uL
• •Platelets (PLT) \>= 75,000/uL
• •Hemoglobin (Hgb) \>= 8 g/dL
• •Total bilirubin =\< 1.5 x upper limits of normal (ULN)
• •Serum glutamic-oxaloacetic transaminase(SGOT)/aspartate aminotransferase (AST) or serum glutamate pyruvate transaminase(SGPT)/alanine aminotransferase (ALT) =\< 3 x ULN
• •Serum creatinine =\< 2 x ULN
• •Prothrombin time(PT)/international normalized ratio(INR) =\< 1.5
• •Electrocardiogram, showing no indications of cardiac problems like congestive heart failure, myocardial infarction, and cardiomyopathy
• •Have been informed of other treatment options
• •Ability to swallow and retain oral medication
• •Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control) prior to study entry; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately
• •Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
• •Patients may have received previous NY-ESO-1 vaccine therapy